Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00247663

Enrollment

Registered

2005-11-02

Start date

1999-12-31

Completion date

Unknown

Last updated

2012-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postmenopausal Women With Advanced Breast Cancer

Keywords

Aromatase inhibitor, letrozole, breast cancer

Brief summary

\- To investigate the safety of letrozole monotherapy at a dose 1.0 mg/day or fadrozole monotherapy at a dose 2.0mg in Japanese postmenopausal patients with advanced breast cancer which participated in double blind study.

Interventions

DRUGLetrozole

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 74 Years

Healthy volunteers

Inclusion criteria

\- Patients which participated in double blind study

Exclusion criteria

* Patients with intolerable toxicity. * Patients which confirmed progressive disease during double blind study. * Patients which have received concurrent anti-cancer therapy during double blind study.

Design outcomes

Primary

Measure	Time frame
Safety during treatment	—

Secondary

Measure	Time frame
No secondary outcomes/objectives planned	—

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026